Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)
1 other identifier
observational
20,000
1 country
1
Brief Summary
The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL). The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form. Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1999
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1999
CompletedFirst Submitted
Initial submission to the registry
June 14, 2017
CompletedFirst Posted
Study publicly available on registry
June 26, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
ExpectedJune 26, 2017
June 1, 2017
22 years
June 14, 2017
June 21, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
lymphoma epidemiology in CZ
occurrence and study of factors influencing the formation of non-hodgkin´s lymphoma from data filled into registry forms by physicians and datamangers
On average once a year
Secondary Outcomes (5)
clinical characteristics
On average once a year
biological characteristics
On average once a year
prognostic systems
On average once a year
therapy used
On average once a year
patients outcome
On average once a year
Study Arms (8)
All NHL subtypes
no interventions
DLBCL
only patients with diffuse large B-cell lymphoma
FL
only patients with follicular lymphoma
MCL
only patients with mantle cell lymphoma
SLL/CLL
only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
MZL
only patients with marginal zone lymphoma
other B-cell lymphomas
only patients with B-lymphomas not described above
T-cell lymphomas
only patients with all types of T-cell lymphoma
Eligibility Criteria
new patients with non-Hodgkin´s lymphoma (NHL)
You may qualify if:
- lymphoma diagnosis
- treated in the Czech Republic
- signed informed consent
You may not qualify if:
- unsigned informed consent
- age \<18 y
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Charles University General Hospital
Prague, 128 08, Czechia
Related Publications (4)
Vodicka P, Janikova A, Belada D, Hanackova V, Mocikova H, Duras J, Steinerova K, Benesova K, Konirova E, Prochazka T, Polgarova K, Masar M, Dlouha J, Blahovcova P, Trneny M. Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. Hematol Oncol. 2025 Nov;43(6):e70142. doi: 10.1002/hon.70142.
PMID: 41108618DERIVEDMocikova H, Pytlik R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Trneny M. Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry. Front Oncol. 2022 May 12;12:874462. doi: 10.3389/fonc.2022.874462. eCollection 2022.
PMID: 35646641DERIVEDVodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022 Aug;109(2):162-165. doi: 10.1111/ejh.13784. Epub 2022 May 11.
PMID: 35502609DERIVEDLobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. 2021 May;35(5):1500-1505. doi: 10.1038/s41375-020-01093-1. Epub 2020 Nov 27. No abstract available.
PMID: 33247178DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marek Trneny, prof. MD
Charles University General Hospital, Prague, CZ
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 14, 2017
First Posted
June 26, 2017
Study Start
January 1, 1999
Primary Completion
December 31, 2020
Study Completion (Estimated)
December 31, 2027
Last Updated
June 26, 2017
Record last verified: 2017-06
Data Sharing
- IPD Sharing
- Will not share
Individual participant data are available only for reasearchers in CLSG.